Aadi Bioscience

Aadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancers patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai on November 2007 and is headquartered in Los Angeles, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Aadi Bioscience reports robust FYARRO sales and optimistic outlook for 2023

Aadi Bioscience showcased strong sales performance and financial stability in 2022.
The company's strengths lie in successful product launches, collaborations, and trial outcomes.
Challenges include managing expenses and meeting expectations for future data releases.
Excitement for 2023 signals potential growth opportunities and continued success.

Aadi Bioscience reports revenue growth and clinical progress in Q1

Aadi Bioscience demonstrated strong performance with revenue growth, progress in clinical trials, and a solid financial position.
The company's strengths lie in its product pipeline, clinical trial advancements, and financial stability, positioning it well for future growth.
While facing challenges in sales growth, trial timelines, and global expansion, Aadi Bioscience has opportunities to diversify its portfolio and explore new markets.

Aadi Bioscience reports robust Q2 earnings and expands pipeline offerings

Aadi Bioscience's Q2 performance reflects strong revenue growth, promising pipeline developments, and a solid financial position, positioning the company for future success.
While facing challenges in managing expenses and clinical trials, the company has opportunities to leverage its momentum, expand its market reach, and drive innovation.
Investors should take note of Aadi Bioscience's strategic advancements and financial stability, signaling potential for growth and value creation in the biopharmaceutical sector.

Aadi Bioscience reports solid Q3 results, advances cancer treatment innovations

Aadi Bioscience's Q3 performance reflects financial stability, increased expenses, and progress in advancing nab-Sirolimus for mutated cancers.
The company's strengths lie in new leadership, innovative treatment potential, and a tumor-agnostic trial approach, positioning it for future success.
Challenges include addressing analyst inquiries, meeting trial timeline goals, and managing financial resources effectively amidst growth and innovation.
Opportunities abound in potentially transforming cancer treatment, showcasing advancements, and expanding the pipeline with innovative approaches.

Aadi Bioscience reports robust sales growth and advances in cancer trials

Aadi Bioscience's strong financial performance in 2023, driven by robust FYARRO sales and a focus on operational efficiency, sets a solid foundation for future growth and innovation.
While challenges exist in managing R&D expenses and trial timelines, the company's strategic measures and positive outlook position them well to capitalize on opportunities in expanding their therapeutic reach.
With ongoing trials showing promising results and a proactive approach to presenting new data, Aadi Bioscience remains committed to advancing novel treatments and delivering value to patients and investors alike.

Aadi Bioscience reports steady Q1 sales and optimistic trial progress

Aadi Bioscience's Q1 performance reflects steady sales and strong cash position supporting future operations.
The company's focus on advancing clinical trials and strategic program alignment positions it for future growth.
Challenges in sales and collaboration changes present areas for ongoing monitoring and strategic adjustments.

Aadi Bioscience reports robust Q2 sales and advances in nab-Sirolimus trials

Aadi Bioscience's Q2 performance reflects steady growth in FYARRO sales and progress in nab-Sirolimus trials for various tumor types.
Despite challenges in meeting expectations and market dynamics, the company's strong financial position and confidence in its products are notable strengths.
With a cash runway into Q4 2025 and a promising pipeline, Aadi is poised for growth and success in the coming years.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai in November 2007 and is headquartered in Los Angeles, CA.

The FDA has approved Aadi Bioscience Inc's (NASDAQ: AADI) Fyarro (sirolimus protein-bound particles for injectable suspension) (albumin-bound) for perivascular epithelioid cell tumor (PEComa). The approval marks the first and only therapy for adult patients for locally advanced unresectable or metastatic malignant PEComa.

Aadi Bioscience Shares Rally On FDA Approval For Its First Product For Rare Form Cancer

LOS ANGELES, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that the U.S. Food and Drug Administration (FDA) has approved FYARRO™ (sirolimus protein-bound particles for injectable suspension) (albumin-bound) for intravenous use for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). FYARRO is the first and only FDA-approved treatment for advanced malignant PEComa in adults.

Aadi Bioscience Announces FDA Approval of its First Product FYARRO™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa)

LOS ANGELES, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced two oral presentations that were made related to its lead candidate, FYARRO™ (ABI-009 or nab-sirolimus) at the Connective Tissue Oncology Society (CTOS) 2021 Annual Meeting, held virtually from November 10-13, 2021. CTOS is a multi-disciplinary group of specialized physicians, medical professionals and scientists from around the world who connect and share their knowledge, experiences and research for the advancement of treatment of sarcomas. Both studies, sponsored by Aadi, provided data in patients with advanced malignant PEComa, which is the clinical indication currently under review by the Food and Drug Administration (FDA) with a November 26, 2021 target Prescription Drug User Fee Act (PDUFA) date.

UPDATE – Aadi Bioscience Presents Two Abstracts on FYARRO (nab-Sirolimus) at the Annual Meeting of the Connective Tissue Oncology Society (CTOS)

LOS ANGELES, Nov. 13, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced two oral presentations that were made related to its lead candidate, FYARRO™ (ABI-009 or nab-sirolimus) at the Connective Tissue Oncology Society (CTOS) 2021 Annual Meeting, held virtually from November 10-13, 2021. CTOS is a multi-disciplinary group of specialized physicians, medical professionals and scientists from around the world who connect and share their knowledge, experiences and research for the advancement of treatment of sarcomas. Both studies, sponsored by Aadi, provided data in patients with advanced malignant PEComa, which is the clinical indication currently under review by the Food and Drug Administration (FDA) with a November 26, 2021 target Prescription Drug User Fee Act (PDUFA) date.

Aadi Bioscience Presents Two Abstracts on FYARRO (nab-Sirolimus) at the Annual Meeting of the Connective Tissue Oncology Society (CTOS)

Aadi Bioscience, Inc. (AADI) delivered earnings and revenue surprises of -132.20% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Aadi Bioscience, Inc. (AADI) Reports Q3 Loss, Misses Revenue Estimates

LOS ANGELES, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today reported financial results for the three and nine months ended September 30, 2021 and provided a general business update.

Aadi Reports Third Quarter 2021 Financial Results and Provides Business Update

LOS ANGELES, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the appointment of Scott Giacobello, CPA, to the role of Chief Financial Officer (CFO) and Treasurer, effective November 28, 2021.   Most recently, Mr. Giacobello was the Chief Financial Officer of GW Pharmaceuticals plc until its $7.2 billion acquisition by Jazz Pharmaceuticals.

Aadi Bioscience Appoints Scott Giacobello as Chief Financial Officer

LOS ANGELES, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the appointment of Loretta M. Itri, M.D., FACP®, to the role of Chief Medical Officer (CMO). Dr. Itri's extensive career spans clinical and regulatory global-leadership roles at both major pharmaceutical and biopharmaceutical companies. Most recently, Dr. Itri was Chief Medical Officer at Immunomedics, Inc, where she oversaw the development program and approval of TRODELVY®, the first TROP-2 directed antibody-drug conjugate for the treatment of unresectable locally advanced or metastatic triple-negative breast and urothelial cancers. Immunomedics was subsequently acquired by Gilead Sciences, Inc.

Aadi Bioscience Appoints Loretta Itri as Chief Medical Officer

Results Published from First Clinical Trial in this Rare Disease Results Published from First Clinical Trial in this Rare Disease

Aadi Bioscience Announces Publication of its Phase 2 Registrational (AMPECT) Trial of nab-Sirolimus in Patients with Malignant Perivascular Epithelioid Cell Tumors in the Journal of Clinical Oncology

LOS ANGELES, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”), a privately-held clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., will present at H.C. Wainwright's 2nd Annual Precision Oncology Conference, which will be held virtually.

Aadi Bioscience to Participate in H.C. Wainwright's 2nd Annual Precision Oncology Conference 2021

- Poster Presentation to go Live on October 7, 2021 at 9 a.m. ET and on Demand at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics -

Aadi Bioscience to Present New Preclinical Data on nab-Sirolimus (ABI-009) at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

LOS ANGELES, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the appointment of Brendan Delaney to the role of Chief Operating Officer (COO). Brendan has had an established career in oncology-focused commercial leadership roles, launching multiple groundbreaking new products and building effective and cohesive commercial teams. Most recently Brendan was Chief Commercial Officer at Constellation Pharmaceuticals, which was acquired by MorphoSys AG for $1.4 billion prior to a commercial launch of pelabresib a first-in-class BETi inhibitor with blockbuster potential across multiple hematology indications. Prior to this, as Chief Commercial Officer at Immunomedics, Inc. Brendan led the launch of TRODELVY®, the first TROP-2 directed antibody-drug conjugate for the treatment of triple-negative breast cancer which was acquired by Gilead Sciences, Inc. for $21 billion.

Aadi Bioscience Appoints Brendan Delaney as Chief Operating Officer

LOS ANGELES, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the appointment of Emma Reeve to its Board of Directors as Audit Committee Chair. Ms. Reeve brings over 25 years of value creation in pharmaceutical, medical device and bio-pharma service companies and a successful track record of transitioning companies from private to public. She currently sits on the boards of PTC Therapeutics (Nasdaq: PTCT) and privately-held Ribon Therapeutics and is Audit Committee Chair at both companies, and was recently appointed to the board of Editas Medicine (Nasdaq: EDIT). Most recently, Ms. Reeve was Chief Financial Officer of Constellation Pharmaceuticals, a development-stage oncology company, which went public in 2018 and raised over $600 million in public and private financings during her tenure. Ms. Reeve was a key member of the team that sold the company to MorphoSys AG for a total consideration of approximately $1.7 billion in 2021.

News for Aadi Bioscience Stock (AADI)